Cargando…
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present final data from OCTAVE Open, an open‐label, long‐term extension study. AIMS: The primary objective of OCTAVE Open was to assess the safety and tolerability of long‐term tofac...
Autores principales: | Sandborn, William J., Lawendy, Nervin, Danese, Silvio, Su, Chinyu, Loftus, Edward V., Hart, Ailsa, Dotan, Iris, Damião, Adérson O. M. C., Judd, Donna T., Guo, Xiang, Modesto, Irene, Wang, Wenjin, Panés, Julian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300081/ https://www.ncbi.nlm.nih.gov/pubmed/34854095 http://dx.doi.org/10.1111/apt.16712 |
Ejemplares similares
-
Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open
por: Panaccione, Remo, et al.
Publicado: (2022) -
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019) -
Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
por: Straatmijer, Tessa, et al.
Publicado: (2022) -
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020) -
Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)